A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids.

Leonida HehlKate T CreasyCecilia VitaliEleonora ScorlettiKatharina S SeelingMara S VellMiriam D RendelDonna ConlonMarijana VujkovicInuk ZandvakiliChristian TrautweinKai M SchneiderDaniel J RaderCarolin Victoria Schneidernull null

Published in: Hepatology communications (2024)

Analyses of the MLXIPL Gln241His polymorphism showed a significant association with a higher risk of SLD diagnosis and elevated serum alanine aminotransferase as well as significantly lower serum triglycerides and apolipoprotein-B levels. MLXIPL might, therefore, be a potential pharmacological target for the treatment of SLD and hyperlipidemia, notably for patients at risk. More mechanistic studies are needed to better understand the role of MLXIPL Gln241His on lipid metabolism and steatosis development.

Keyphrases

end stage renal disease
high fat diet
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
high fat diet induced
patient reported